Preclinical Development of a Novel, Orally-Administered Anti-Tumour Necrosis Factor Domain Antibody for the Treatment of Inflammatory Bowel DiseaseJenny Crowe, Michael R. West|Scientific Reports|2018Cited by 58
Oral Anti-Tumour Necrosis Factor Domain Antibody V565 Provides High Intestinal Concentrations, and Reduces Markers of Inflammation in Ulcerative Colitis PatientsSuhail Nurbhai, Jenny Crowe|Scientific Reports|2019Cited by 38
The parasitic worm product ES-62 promotes health- and life-span in a high calorie diet-accelerated mouse model of ageingJenny Crowe, Margaret M. Harnett, James Doonan et al.|PLoS Pathogens|2020Cited by 38